Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.

Pediatric nephrology (Berlin, Germany) - 1 Jan 2016

Zhang Yanqin, Wang Fang, Ding Jie, Zhang Hongwen, Liu Xiaoyu, Wang Suxia, Xiao Huijie, Yao Yong, Liu Jingcheng, Zhong Xuhui, Guan Na, Su Baige, Wu Guohong, Yu Lixia

Abstract excerpt

BACKGROUND: The aim of this study was to analyze the long-term efficacy and safety of angiotensin-converting enzyme inhibitor (ACEi) and ACEi + angiotensin receptor blocker (ARB) treatments in a cohort of children with Alport syndrome (AS). METHODS: This was a respective review of 79 Chinese children with AS who received ACEi alone or combined ACEi + ARB therapy. RESULTS: The mean age of the pediatric patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme Inhibitors
Share to Angiotensin II Type 1 Receptor Blockers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Collagen Type IV

Share to Creatinine

Share to Drug Therapy, Combination

Share to Kidney Failure, Chronic

Share to Nephritis, Hereditary

Share to Proteinuria

Source

Identifiers

PMID: 26248473
DOI: 10.1007/s00467-015-3184-5

Genes

ACE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.PMID 26248473Read ↗

Current and Future Therapeutical Options in Alport Syndrome.Semantic proximity Read ↗

Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome.Semantic proximity Read ↗

An update on the pathomechanisms and future therapies of Alport syndrome.Semantic proximity Read ↗

Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations.Semantic proximity Read ↗

A novel compound heterozygous COL4A4 mutation in a Chinese family with Alport syndrome: A care case report.Semantic proximity Read ↗

Exploration of Gene Therapy for Alport SyndromeSemantic proximity Read ↗

Treatment of Alport syndrome: beyond animal models.Semantic proximity Read ↗

[Alport syndrome: Hereditary nephropathy associated with mutations in genes coding for type IV collagen chains].Semantic proximity Read ↗

Lifelong effect of therapy in young patients with the <i>COL4A5</i> Alport missense variant p.(Gly624Asp): a prospective cohort studySemantic proximity Read ↗

Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene.Semantic proximity Read ↗

Dissecting the genotype-phenotype correlation of COL4A5 gene mutation and its response to renin-angiotensin-aldosterone system blockers in Chinese male patients with Alport syndrome.Semantic proximity Read ↗

Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.